Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly(A) RNA polymerase non-canonical PAPD5 (PAPD5) is an **RNA-processing enzyme** that catalyzes the addition of short poly(A) tails, and sometimes guanosine residues, to the 3′ ends of RNA molecules[1][4]. Unlike canonical poly(A) polymerases, PAPD5 acts in **RNA quality control** by tagging misprocessed, aberrant, or noncoding RNAs for further degradation, thus helping to maintain proper RNA homeostasis in eukaryotic cells[1]. PAPD5 is also a critical host factor in the life cycle of hepatitis B virus (HBV): it protects viral RNA by maintaining the integrity of its poly(A) tails, making it a promising antiviral **therapeutic target**[2][3]. Small-molecule inhibitors such as AB-452 and RG7834 inhibit PAPD5, causing degradation of HBV RNAs and significant reductions in viral protein production[2][3]. The enzyme is a member of the noncanonical poly(A) polymerase family and is sometimes referred to as TENT4B or TRF4-2[4]. There are no widely recognized patient selection or efficacy biomarkers for non-viral diseases at this time.
Inhibition of PAPD5 leads to destabilization of viral RNA (especially HBV RNA) by impairing poly(A) tail maintenance, promoting degradation - Inhibitors prevent the stabilization and correct tailing of viral RNAs, decreasing viral protein expression and replication
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly(A) RNA polymerase non-canonical PAPD5 (PAPD5).